Breast Cancer

ASCO® Meeting Library

Access official Highlights of the Day and Education Session videos and slides.
Plenary Session
A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
Presenter: Wendy Y. Chen
Session Title: ASCO Plenary Series: February 2022 Session
Meeting: ASCO Plenary Series
Education Session
HER-2/Neu Therapeutics
Speaker: Patricia LoRusso, DO
Session Title: ASCO/American Association for Cancer Research (AACR) Joint Session: HER-2/Neu Alterations–Using Biology to Drive Therapeutic Options in Cancers of the Breast, Gut, and Beyond
Meeting: 2021 ASCO Annual Meeting
Browse All Sessions
Education Session
Addressing the Standard of Care in Adjuvant Therapy for Premenopausal Women
Speaker: Vered Stearns, MD, FASCO
Session Title: The Controversies of Adjuvant Therapies for Premenopausal Women Diagnosed With Luminal Breast Cancers
Meeting: 2021 ASCO Annual Meeting
Browse All Sessions

ASCO® Educational Book

Read peer-reviewed articles authored by the 2021 Annual Meeting Education Program faculty.
Harnessing Nutrition and Physical Activity for Breast Cancer Prevention and Control to Reduce Racial/Ethnic Cancer Health Disparities
The authors review the current evidence for racial/ethnic disparities in obesity and breast cancer risk and survival, discuss the evolution of nutrition/physical activity guidelines for cancer prevention and control, and provide an overview of lifestyle interventions, including barriers and facilitators in implementation and dissemination science among minority populations underrepresented in research.
Disparities in Breast Cancer Associated With African American Identity
Persistent disparities in the burden of breast cancer between African Americans and White Americans have been documented over many decades.
Browse All Chapters

ASCO® Guidelines

View recently published clinical practice guidelines from ASCO.
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer.
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.
Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline.
Browse All Guidelines

ASCO® Education

Take a selection of ASCO Education eLearning courses.
Treatment of an Older Patient with Early-Stage, HER2-Positive Breast Cancer
This case-based course details the multi-step process of treatment decision-making for an older woman with early-stage, HER2-positive and hormone receptor-positive breast cancer.
First-line Treatment: HR-Positive and HER2-Positive Metastatic Breast Cancer
This case-based course discusses implementation of recent clinical research findings regarding therapy for hormone receptor-positive, HER2-positive, metastatic breast cancer into clinical practice.
Screening and Prevention of Breast Cancer
This course discusses modifiable risk factors for breast cancer and approaches to breast cancer risk assessment, including risk assessment tools and models. Breast cancer screening recommendations are described, along with key screening and diagnostic tools.
Browse All Courses

ASCO Daily News®

Stay updated with news from ASCO’s official conference reporter.
ASCO Refines Guidance on Using Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
April 27, 2022
Prosigna and the Breast Cancer Index may be used in postmenopausal patients with breast cancer that is node-negative, ER-positive, and HER2-negative.
ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage TNBC
April 20, 2022
The guideline update recommends pembrolizumab in combination with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery, for patients with T1cN1-2 to T2-4N0 early-stage TNBC.
Remote Behavioral Weight Loss Intervention Is Effective for Breast Cancer Survivors
April 13, 2022
Approximately one-half of breast cancer survivors receiving a behavioral weight loss intervention, with or without the addition of pharmacotherapy, achieved at least 5% weight loss at 8 weeks.
Browse All News
Sign up for new content alerts

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.

Take survey
No thanks, not at this time